Anavex Life Sciences Corp. (AVXL) News
Filter AVXL News Items
AVXL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AVXL News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest AVXL News From Around the Web
Below are the latest news stories about ANAVEX LIFE SCIENCES CORP that investors may wish to consider to help them evaluate AVXL as an investment opportunity.
Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, J |
Are Medical Stocks Lagging Anavex Life Sciences (AVXL) This Year?Here is how Anavex Life Sciences (AVXL) and AbbVie (ABBV) have performed compared to their sector so far this year. |
All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to BuyAnavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Anavex price target raised to $42 from $40 at H.C. WainwrightH.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Anavex (AVXL) to $42 from $40 and keeps a Buy rating on the shares after the company announced the acceptance of the blarcamesine Marketing Authorization Application for the treatment of Alzheimer’s disease for review by the European Medicines Agency. The “timely acceptance” of the MAA for blarcamesine reflects at least in part the EMA’s recognition of the severe unmet medical need in Alzheimer’s, the analyst tells inve |
Anavex Life Sciences Faces Manufacturing Challenges Impacting Product Launch and Financial StabilityAnavex Life Sciences (AVXL) has disclosed a new risk, in the Manufacturing category. Anavex Life Sciences faces potential risks associated with material modifications in the manufacturing methods of its product candidates. As these candidates transition from preclinical studies to commercialization, changes in manufacturing techniques can lead to increased costs, delays, and the necessity for additional studies. Such alterations may cause variations in product performance, impacting clinical tri |
We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash BurnJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Anavex Life Sciences Corp (AVXL) Q4 2024 Earnings Call Highlights: Strong Cash Position and ...Anavex Life Sciences Corp (AVXL) reports a robust cash runway and significant progress in Alzheimer's research, despite ongoing financial challenges. |
Q4 2024 Anavex Life Sciences Corp Earnings CallQ4 2024 Anavex Life Sciences Corp Earnings Call |
Anavex Life Sciences: Fiscal Q4 Earnings SnapshotNEW YORK (AP) — Anavex Life Sciences Corp. AVXL) on Monday reported a loss of $11.6 million in its fiscal fourth quarter. On a per-share basis, the New York-based company said it had a loss of 14 cents. |
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business UpdateCompany to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its fourth |